Your browser doesn't support javascript.
loading
Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Xu, Peng-Peng; Shi, Zi-Yang; Qian, Ying; Cheng, Shu; Zhu, Yue; Jiang, Lu; Li, Jian-Feng; Fang, Hai; Huang, Heng-Ye; Yi, Hong-Mei; Ouyang, Bin-Sheng; Wang, Li; Zhao, Wei-Li.
Afiliación
  • Xu PP; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Shi ZY; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Qian Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Cheng S; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Zhu Y; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Jiang L; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Li JF; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Fang H; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai.
  • Huang HY; School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Yi HM; Department of Pathology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Ouyang BS; Department of Pathology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wang L; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai; Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China.
  • Zhao WL; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai; Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Shanghai, China. Electronic address: zhao.weili@yahoo.co
Lancet Healthy Longev ; 3(7): e481-e490, 2022 07.
Article en En | MEDLINE | ID: mdl-36102758
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anciano Frágil / Linfoma de Células B Grandes Difuso Tipo de estudio: Clinical_trials Límite: Aged / Humans País/Región como asunto: Asia Idioma: En Revista: Lancet Healthy Longev Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Anciano Frágil / Linfoma de Células B Grandes Difuso Tipo de estudio: Clinical_trials Límite: Aged / Humans País/Región como asunto: Asia Idioma: En Revista: Lancet Healthy Longev Año: 2022 Tipo del documento: Article